H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)

June 30, 2026 6:44 AM

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $36.00 price target on 4D Molecular Therapeutics (NASDAQ: FDMT).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found